Features | VJHemOnc

ASH 2019 Late-Breaking Abstracts

VJHemOnc are excited to present the incredibly exciting late-breaking research presented at this years American Society of Hematology (ASH) 2019…

iwCAR-T 2019 e-learning

VJHemOnc is pleased to bring you e-learning webcasts from iwCAR-T 2019– explore updates in CAR T-cell therapy!

PROMISE

The Video Journal of Hematological Oncology (VJHemOnc) is pleased to share the success of the PROMISE study by the Dana-Faber…

The REAL classification of lymphoma

Twenty-five years ago, almost to the day, there was a paradigm shift in the classification of lymphoma.

Selinexor granted accelerated FDA approval for multiple myeloma

The pivotal STORM study (NCT02336815) welcomed selinexor (Xpovio), in combination with low-dose dexamethasone, into the treatment line for quad/penta-refractory multiple…

In vitro data suggests dasatinib prevents cytokine release syndrome in CAR T-cell therapy

CAR T-cell therapy has taken the oncology community by storm in recent years, and although it has proven extremely successful,…

iwNHL 2018
E-learning

VJHemOnc is pleased to bring e-learning webcasts from iwNHL 2018- explore updates in lymphoma!

iwAL 2019
E-learning

VJHemOnc is pleased to bring you e-learning webcasts from iwAL 2019. Catch up on key topics in acute leukemias now!